Peripheral pulmonary nodule
Conditions
Interventions
Plasma cryoablation group:plasma cryoablation
Combined cryoablation and thermal ablation group:combined cryoablation and thermal ablation
Sponsors
Tianjin Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age = 18 years; 2. The main lesions planned to be ablated are confirmed by pathology, and other lesions planned to be ablated are confirmed by pathology or clinically assessed as primary non-small cell lung cancer or pulmonary metastatic tumor (the primary disease of the subjects with pulmonary metastatic tumor is well controlled); In situ recurrence of lung cancer; 3. Number of unilateral lung lesions: = 3 (except multiple primary lung cancer); 4. The size of each lung lesion: = 3cm; 5. Subjects refused surgery or could not tolerate surgery according to clinical evaluation; 6. Subjects refuse or are considered unsuitable for radiotherapy/chemotherapy, or have no reaction to previous radiotherapy/chemotherapy, or have disease progression after radiotherapy/chemotherapy; 7. According to the evaluation of the investigator, it is feasible to reach the target lesion through percutaneous puncture and perform ablation; 8. Subjects in the Eastern Tumor Cooperation Group (ECOG) with physical condition score: = 3; 9. The subject agreed to receive local ablation for pulmonary lesions.
Exclusion criteria
Exclusion criteria: 1. Subjects with severe bleeding tendency and irreversible coagulation disorder; Or before ablation subjects who stopped anticoagulation treatment and/or antiplatelet drugs for less than 7 days; 2. Subjects who found intrathoracic lymph node or extrapulmonary metastasis within 1 month of preoperative examination (except extrapulmonary metastasis controlled by local treatment); 3. The ablation focus is planned to receive radiotherapy in the past 6 months; 4. Subjects with high-risk diseases; 5. The nearest distance between tumor and trachea, main bronchus, esophagus, aortic arch branch, main pulmonary artery, left and right pulmonary arteries and heart is less than 2cm; 6. Subjects who have participated in or are participating in other clinical studies in the past 30 days 7. Subjects who were pregnant or had a pregnancy plan during the study; 8. Other subjects identified by the researcher to be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| local control rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival (PFS);overall survival(OS);cancer-specific survival; | — |
Countries
China
Contacts
Public ContactDaqiang Sun
Tianjin Chest Hospital
Outcome results
None listed